
About T3 MGen
T3 MGen is a Healthcare company based in Bengaluru (India) founded in 2021 by Narendra Dnyanoba Dhele, Shankarrao Baburao Patil, and Nameirakpam Bunindro Singh. It develops proprietary technologies for immune therapeutics against diseases using AI and multidisciplinary research. It operates on a B2B and Research Collaboration model. The company has 1 employees. Its chief executive, as recorded, is Narendra Dnyanoba Dhele. T3 MGen offers products and services including Therapeutic Bioactive Peptidomers, Differentiative Biomarkers for IBD, and Small Molecules as T reg Modulators. Its focus areas include Biotechnology, Biomarkers, Inflammatory Diseases and Drug Discovery. Its legal entity in India is T-3 Molecular Genetics (T-3 Mgen) Private Limited (U73100KA2021PTC149735).
Company details
T3 Molecular Genetics is a seed-stage biotechnology company based in Bengaluru, India, focusing on solving unmet challenges in life sciences. Their multidisciplinary team of molecular biologists, data scientists, and immunologists innovates immune cell modulation technologies. They use AI, ML, and cutting-edge tools for peptide engineering, biomarker discovery, and small molecule screening to develop therapeutics for inflammatory and infectious diseases. Collaborations with institutions drive their research activities.
- Headquarters Bengaluru, India
- Employees 1
- Founders Narendra Dnyanoba Dhele, Shankarrao Baburao Patil, Nameirakpam Bunindro Singh
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website t3mgen.com
- Social LinkedIn
- Legal Name T-3 Molecular Genetics (T-3 Mgen) Private Limited
- Date of Incorporation 20 Jul, 2021
- Jurisdiction Bangakore, Karnataka, India
- Annual Revenue₹30,060
FY 2023 · -60% YoY
- Net Loss-₹1.6 Lakh
FY 2023 · -540% margin
- EBITDA-₹1.2 Lakh
FY 2023 · -387% margin
- Employee Count1
Associated legal entities of T3 MGen
T3 MGen operates through T-3 Molecular Genetics (T-3 Mgen) Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2023) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| T-3 Molecular Genetics (T-3 Mgen) Private Limited CIN U73100KA2021PTC149735 | Active | 20 Jul 2021 | Bangalore, Karnataka | ₹0.0 Cr | 3 | View details |
Products & Services of T3 MGen
T3 MGen offers a comprehensive portfolio of products and services, including Therapeutic Bioactive Peptidomers, Differentiative Biomarkers for IBD, and Small Molecules as T reg Modulators.
Identifies and engineers biopeptides for clinical uses with AI and ML tools.
Targets early diagnosis of ulcerative colitis and Crohn's disease through research.
Screens natural compounds to modulate T regulatory cells for disease treatment.
Board of directors of T-3 Molecular Genetics (T-3 Mgen) Private Limited (T3 MGen)
T-3 Molecular Genetics (T-3 Mgen) Private Limited is the primary company behind T3 MGen. The board of T-3 Molecular Genetics (T-3 Mgen) Private Limited currently have 3 directors; the longest-serving is Narendra Dnyanoba Dhele, appointed in 2021.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Narendra Dnyanoba Dhele DIN 09247526 | Director | 20 Jul 2021 | 5 yrs 3 mo | T-3 Molecular Genetics (T-3 Mgen) Private Limited |
| Shankarrao Baburao Patil DIN 09247527 | Director | 20 Jul 2021 | 5 yrs 3 mo | T-3 Molecular Genetics (T-3 Mgen) Private Limited |
| Nameirakpam Bunindro Singh DIN 09247528 | Director | 20 Jul 2021 | 5 yrs 3 mo | T-3 Molecular Genetics (T-3 Mgen) Private Limited |
People of T3 MGen
3 people are tracked at T3 MGen (3 in leadership); the tracked headcount is 1.
| Name | Role | Group |
|---|---|---|
| Co-Founder, CEO | Leadership | |
| Co-Founder | Leadership | |
| Co-Founder | Leadership |
Complete people profiles for T3 MGen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of T3 MGen
Figures of T-3 Molecular Genetics (T-3 Mgen) Private Limited, the primary company behind T3 MGen, for FY 2023. Revenue was ₹30,060 (-60% year on year). Net loss was -₹1.6 Lakh (-540% margin). EBITDA was -₹1.2 Lakh (-387% margin).
- ₹30,060Revenue · FY 2023 · -60% YoY
- -₹1.6 LakhNet loss · -540% margin
- -₹1.2 LakhEBITDA · -387% margin
- ₹1.1 LakhPaid-up capital
Balance sheet, profit and loss, cash flow and ratios of T-3 Molecular Genetics (T-3 Mgen) Private Limited are on its company page.
Detailed financial statements for T3 MGen
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about T3 MGen
T3 MGen was founded in 2021.
T3 MGen is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
Narendra Dnyanoba Dhele is the CEO of T3 MGen, as recorded in our data. They have also founded this company.
T3 MGen has 1 employees.
The primary company behind T3 MGen, T-3 Molecular Genetics (T-3 Mgen) Private Limited, reported revenue of βΉ30,060 for FY 2023, down 60% year on year.
T3 Molecular Genetics is a seed-stage biotechnology company based in Bengaluru, India, focusing on solving unmet challenges in life sciences. Their multidisciplinary team of molecular biologists, data scientists, and immunologists innovates immune cell modulation technologies. They use AI, ML, and cutting-edge tools for peptide engineering, biomarker discovery, and small molecule screening to develop therapeutics for inflammatory and infectious diseases. Collaborations with institutions drive their research activities.
T3 MGen offers Therapeutic Bioactive Peptidomers, Differentiative Biomarkers for IBD, and Small Molecules as T reg Modulators.
T3 MGen operates through T-3 Molecular Genetics (T-3 Mgen) Private Limited.
The legal entities of T3 MGen currently have 3 directors, including Narendra Dnyanoba Dhele, Shankarrao Baburao Patil, Nameirakpam Bunindro Singh.